113 related articles for article (PubMed ID: 25420854)
41. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
42. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
43. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis.
Zhao YJ; Wen JQ; Cheng K; Ming YZ; She XG; Liu H; Liu L; Ye QF; Ding BN
Transplant Proc; 2013; 45(6):2226-32. PubMed ID: 23953533
[TBL] [Abstract][Full Text] [Related]
44. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
45. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation.
Rangel EB; Melaragno CS; Sá JR; Gonzalez AM; Linhares MM; Salzedas A; Medina-Pestana JO
Transplant Proc; 2009 Dec; 41(10):4265-9. PubMed ID: 20005381
[TBL] [Abstract][Full Text] [Related]
46. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
[TBL] [Abstract][Full Text] [Related]
47. Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Reinke P; Budde K; Hugo C; Petersen P; Schnuelle P; Fricke L; Scholz D; Sperschneider H; Bahner U; Kramer S; Fischer W; Arns W
Transplant Proc; 2011 Jun; 43(5):1641-6. PubMed ID: 21693250
[TBL] [Abstract][Full Text] [Related]
48. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications.
Miras M; Carballo F; Egea J; Martínez C; Alvarez-López MR; Sánchez-Bueno F; Parrilla P
Transplant Proc; 2007 Sep; 39(7):2314-7. PubMed ID: 17889175
[TBL] [Abstract][Full Text] [Related]
49. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
50. The Burden of Gastrointestinal Complaints in Kidney Transplant Recipients Using Tacrolimus With and Without Mycophenolate Mofetil: A Randomized Controlled Study.
Fatly ZA; Betjes MG; van Gestel J; Verschragen M; de Weerd AE
Front Nephrol; 2022; 2():933954. PubMed ID: 37675013
[TBL] [Abstract][Full Text] [Related]
51. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
52. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
[TBL] [Abstract][Full Text] [Related]
53. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
[TBL] [Abstract][Full Text] [Related]
54. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
[TBL] [Abstract][Full Text] [Related]
55. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: comparison between mycophenolate sodium and mycophenolate mofetil.
Laftavi MR; Hai F; Laftavi H; Feng L; Said M; Patel S; Kohli R; Alnimri M; Dayton M; Pankewycz O
Transplant Proc; 2011 Mar; 43(2):478-81. PubMed ID: 21440738
[TBL] [Abstract][Full Text] [Related]
56. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of tolerability of enteric-coated mycophenolate sodium versus mycophenolate mofetil in de novo renal transplantation.
Pacheco e Silva Filho A; Manfro RC; Contieri FL; Mazzali M; Garcia VD; Carvalho Dde B; David S; Machado P; Rodrigues CA
J Bras Nefrol; 2015; 37(3):291-6. PubMed ID: 26398638
[TBL] [Abstract][Full Text] [Related]
58. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
Tsai MK; Hu RH; Lee CJ; Lee PH
J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
[TBL] [Abstract][Full Text] [Related]
60. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients.
Sun Q; Liu ZH; Yin G; Chen H; Chen J; Ji S; Li LS
Nephrol Dial Transplant; 2006 Feb; 21(2):510-7. PubMed ID: 16421166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
